The Health Hub for Builders
The intelligence platform connecting breakthrough healthcare ideas with the investors who bring them to life.
What Investors Receive
Every qualified opportunity arrives as a confidential investment memo — scored across 10 factors, verified by two experts.
CONFIDENTIAL INVESTMENT MEMO
SH-INN-2026-00047
Vertical
Biotech
Stage
Phase II
Country
France
Raising
€15M
Summary
Clinical-stage biotech developing a first-in-class oral therapy for a large inflammatory disease indication. Phase II data showed statistically significant efficacy (p<0.001). Strong IP portfolio with 12 granted patents. Experienced management team with 2 prior exits. Seeking Series B to fund Phase III.
Compatibility Breakdown
Identity revealed only after mutual interest + NCA
What Startups & Funds Receive
When an allocator matches your profile, you receive a scored interest memo — verified mandate, ticket size, and compatibility breakdown.
ALLOCATOR INTEREST MEMO
SH-ALC-2026-00012
Type
Multi-Family Office
Country
Saudi Arabia
Ticket
€2M – €10M
Sectors
Biotech, Medtech
Mandate Summary
Seeking Series A–B healthcare companies in Europe with strong IP and clinical data. Preference for biotech and medtech with clear regulatory pathways. Open to co-investment. Time horizon: 5–7 years. Actively deploying from a €120M healthcare allocation.
Compatibility Breakdown
Identity revealed only after mutual interest + NCA
From Application to Introduction
A four-step process designed to protect both sides and ensure quality.
You apply
3 minShort form: your stage, sector, ticket size, geography. No fees, no commitment.
We verify both sides
48hMohamed qualifies the science. Jamil qualifies the finance. Only verified parties enter.
You receive scored memos
OngoingAnonymized profiles with a compatibility score out of 100, broken down across 10 factors.
Mutual interest → Introduction
You decideBoth sides confirm interest. NCA signed. Identities revealed. We facilitate the first meeting.
Intelligence Hub
Explore healthcare verticals. Live market intelligence, sourced and verified.
20 results
LiveAntimicrobial Resistance: The $100 Trillion Health Crisis Pharma Can't Ignore
Sabil Health
Antimicrobial Resistance: The $100 Trillion Health Crisis Pharma Can't Ignore
1.27M
deaths in 2019
10M/yr
by 2050
12
new antibiotics since 2017